Gepotidacin

Synonym(s): GSK2140944

Class: Bacterial topoisomerase inhibitor

Spectrum of activity:	Gram-positive  &  Gram-negative
Details of activity:	Treatment of conventional and biothreat pathogens including MRSA. Respiratory tract infections, acute bacterial skin and skin structure infections (ABSSI), uncomplicated urogenital gonorrhoea
Institute where first reported:	GlaxoSmithKline, UK
Year first mentioned:	2011
Highest developmental phase:	Phase 3
Development status:	Active

Chemical structure(s):
Canonical SMILES:	C1CC2=C(C=NC(=C2)CNC3CCN(CC3)C[C@@H]4CN5C(=O)C=CC6=C5N4C(=O)C=N6)OC1
Isomeric SMILES:	C1CC2=CC(=NC=C2OC1)CNC3CCN(CC3)C[C@@H]4CN5C(=O)C=CC6=C5N4C(=O)C=N6
InChI:	InChI=1S/C24H28N6O3/c31-22-4-3-20-24-29(22)15-19(30(24)23(32)13-27-20)14-28-7-5-17(6-8-28)25-11-18-10-16-2-1-9-33-21(16)12-26-18/h3-4,10,12-13,17,19,25H,1-2,5-9,11,14-15H2/t19-/m1/s1
InChI Key:	PZFAZQUREQIODZ-LJQANCHMSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/25101874

External links:
Guide to Pharmacology:	gepotidacin
Main Source:	https://www.gsk-clinicalstudyregister.com/search/?search_terms=GSK2140944
Citation:	https://clinicaltrials.gov/ct2/show/NCT02045797
Patent:	WO2021219637A1